247 related articles for article (PubMed ID: 31648474)
21. [Comparison of efficacy of first-line administration of generic dasatinib or imatinib in patients with Philadelphia chromosome positive acute lymphoblastic leukemia treated by hematopoietic stem cell transplantation].
Yang F; Cai WZ; Huang XW; Xue SL; Fu CC; Tang XW; Sun AN; Wu DP; Qiu HY
Zhonghua Xue Ye Xue Za Zhi; 2018 Aug; 39(8):661-667. PubMed ID: 30180468
[No Abstract] [Full Text] [Related]
22. T315I mutation exerts a dismal prognosis on adult BCR-ABL1-positive acute lymphoblastic leukemia, and salvage therapy with ponatinib or CAR-T cell and bridging to allogeneic hematopoietic stem cell transplantation can improve clinical outcomes.
Ting S; Mixue X; Lixia Z; Xueying L; Wanzhuo X; Xiujin Y
Ann Hematol; 2020 Apr; 99(4):829-834. PubMed ID: 32107574
[TBL] [Abstract][Full Text] [Related]
23. [Imatinib in combination with allogeneic hematopoietic stem cell transplantation improved the outcome of adult Philadelphia chromosome-positive acute lymphoblastic leukemia].
Cheng Z; Zhao L; Chen G; Wu D; Qiu H; Tang X; Fu C; Jin Z; Chen F; Xue S; Sun A
Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):114-9. PubMed ID: 24606651
[TBL] [Abstract][Full Text] [Related]
24. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.
Soverini S; De Benedittis C; Papayannidis C; Paolini S; Venturi C; Iacobucci I; Luppi M; Bresciani P; Salvucci M; Russo D; Sica S; Orlandi E; Intermesoli T; Gozzini A; Bonifacio M; Rigolin GM; Pane F; Baccarani M; Cavo M; Martinelli G
Cancer; 2014 Apr; 120(7):1002-9. PubMed ID: 24382642
[TBL] [Abstract][Full Text] [Related]
25. [Prognostic significance of Ph-positive acute lymphoblastic leukemia].
Zhou L; Hu J; Chen J; Du S; Wang A; You J; Wu W; Shen Z; Li J
Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):109-13. PubMed ID: 24606650
[TBL] [Abstract][Full Text] [Related]
26. [Clinical Characteristics of Patients with Ph
Jia YN; Li Y; Gong XY; Liu KQ; Ye L; Wang HJ; Li QH; Li CW; Wang Y; Wang JX; Mi YC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Apr; 27(2):354-359. PubMed ID: 30998137
[TBL] [Abstract][Full Text] [Related]
27. [Clinical study of imatinib for treatment of Philadelphia chromosome positive acute lymphoblastic leukemia.].
Li CX; Wu DP; Liu H; Liu YJ; Ma X; Wu XJ; Chen XC; Sun DP
Zhonghua Xue Ye Xue Za Zhi; 2010 Mar; 31(3):181-5. PubMed ID: 20510109
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic approach and outcome of children with Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors: An SFCE retrospective study.
Aubert L; Petit A; Bertrand Y; Ray-Lunven AF; Angoso M; Pluchart C; Millot F; Saultier P; Cheikh N; Pellier I; Plantaz D; Sirvent A; Thouvenin-Doublet S; Valduga J; Plat G; Rialland F; Henry C; Esvan M; Gandemer V
Pediatr Blood Cancer; 2022 Feb; 69(2):e29441. PubMed ID: 34854546
[TBL] [Abstract][Full Text] [Related]
29. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
[TBL] [Abstract][Full Text] [Related]
30. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
Meggyesi N; Kozma A; Halm G; Nahajevszky S; Bátai A; Fekete S; Barta A; Ujj G; Lueff S; Sipos A; Adám E; Bors A; Reményi P; Masszi T; Tordai A; Andrikovics H
Acta Haematol; 2012; 127(1):34-42. PubMed ID: 22005133
[TBL] [Abstract][Full Text] [Related]
31. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
[TBL] [Abstract][Full Text] [Related]
32. Treatment of elderly patients with acute lymphoblastic leukemia--evidence for a benefit of imatinib in BCR-ABL positive patients.
Brandwein JM; Gupta V; Wells RA; Schuh AC; Schimmer AD; Lipton JH; Messner HA; Yi QL; Chun K; Kamel-Reid S; Minden MD
Leuk Res; 2005 Dec; 29(12):1381-6. PubMed ID: 15927253
[TBL] [Abstract][Full Text] [Related]
33. Tyrosine kinase inhibitor use in pediatric Philadelphia chromosome-positive acute lymphoblastic anemia.
Hunger SP
Hematology Am Soc Hematol Educ Program; 2011; 2011():361-5. PubMed ID: 22160058
[TBL] [Abstract][Full Text] [Related]
34. Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL.
Hatta Y; Mizuta S; Matsuo K; Ohtake S; Iwanaga M; Sugiura I; Doki N; Kanamori H; Ueda Y; Yoshida C; Dobashi N; Maeda T; Yujiri T; Monma F; Ito Y; Hayakawa F; Takeuchi J; Kiyoi H; Miyazaki Y; Naoe T
Ann Hematol; 2018 Sep; 97(9):1535-1545. PubMed ID: 29694642
[TBL] [Abstract][Full Text] [Related]
35. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
36. [Risk Factors of Leukemia-free Survival in Ph
Bao XB; Cai WZ; He XF; Chen SN; Qiu HY; Sun AN; Wu DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1787-1792. PubMed ID: 29262917
[TBL] [Abstract][Full Text] [Related]
37. Outcome of treatment in adults with Philadelphia chromosome-positive and/or BCR-ABL--positive acute lymphoblastic leukemia-retrospective analysis of Polish Adult Leukemia Group (PALG).
Wrzesień-Kuś A; Robak T; Pluta A; Zwolińska M; Wawrzyniak E; Wierzbowska A; Skotnicki A; Jakubas B; Hołowiecki J; Nowak K; Kuliczkowski K; Mazur G; Haus O; Dmoszyńska A; Adamczyk-Cioch M; Jedrzejczak WW; Paluszewska M; Konopka L; Pałynyczko G
Ann Hematol; 2006 Jun; 85(6):366-73. PubMed ID: 16523310
[TBL] [Abstract][Full Text] [Related]
38. [Allogeneic hematopoietic stem cell transplantation for treatment of Philadelphia chromosome positive acute lymphoblastic leukemia].
Xu LP; Huang XJ; Liu KY; Chen H; Liu DH; Zhang YC; Chen YH; Han W; Gao ZY; Lu DP
Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Jun; 37(3):231-5. PubMed ID: 15968308
[TBL] [Abstract][Full Text] [Related]
39. Successful second allogeneic stem cell transplantation in second remission induced by dasatinib in a child with Philadelphia chromosome positive acute lymphoblastic leukemia.
Millot F; Cividin M; Brizard F; Chomel JC; Méchinaud F; Guilhot F
Pediatr Blood Cancer; 2009 Jul; 52(7):891-2. PubMed ID: 19202569
[TBL] [Abstract][Full Text] [Related]
40. Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusion.
Oya S; Morishige S; Ozawa H; Sasaki K; Semba Y; Yamasaki Y; Nakamura T; Aoyama K; Seki R; Mouri F; Osaki K; Miyamoto T; Maeda T; Nagafuji K
Int J Hematol; 2021 Feb; 113(2):285-289. PubMed ID: 32951102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
